Dyax: We’re Fixed On Growth, Not A Buyout
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech outlines strategy to reduce cash burn, increase revenue while advancing lead compound.
You may also be interested in...
Dyax’s HAE Candidate Meets Clinical Endpoints In Phase III Trial
With the completion of Phase III testing, Dyax plans to submit final piece of rolling BLA for DX-88 in early fourth quarter.
Dyax’s HAE Candidate Meets Clinical Endpoints In Phase III Trial
With the completion of Phase III testing, Dyax plans to submit final piece of rolling BLA for DX-88 in early fourth quarter.
Creative Dyax Buys Back Royalty Rights Through Better-Terms Cowen Loan
Italy’s Dompe Farmaceutici waiting for next month’s HAE data to decide on European deal.